You are here: Industry Insights > Market News > M&As this week: Guanhao Biotech, Cancer Genetics, Alvogen

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

CBZ-L-Valganciclovir

4-Bromo-3-nitroanisole

PF-680Adjustable Cellophane Tri-dimensiona Overwrapping Machine (with tear type)

2-Chlorophenothiazine

Flibanserin

its control software

M&As this week: Guanhao Biotech, Cancer Genetics, Alvogen

pharmaceutical-technologyAugust 21, 2017

Tag: Guanhao Biotech , Cancer Genetics , Alvogen

Favorites

M&As this week: Guanhao Biotech, Cancer Genetics, Alvogen - Pharmaceutical Technology

Chinese biotechnology company Guanhao Biotech plans to acquire a 53.4% stake in two pharmaceutical companies based in China for CNY266m ($39.95m).

US-based pharmaceutical company Cancer Genetics Inc (CGI) plans to acquire Australian preclinical oncology services provider vivoPharm for $12m. The acquisition is expected to strengthen CGI’s business.

South Korean pharmaceutical company Alvogen plans to acquire Russian pharmaceutical firm Omega Bittner from Irish healthcare company Perrigo Company.

The acquisition will strengthen Alvogen’s business in Russia.

Previous:Cadila Pharma observes ‘Swachhta Pakhwada’

Next:Cancer Research UK and Newcastle University extend drug discovery partnership with Astex

InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China

PharmaSourcesJuly 04, 2025

InnoCare Pharmaannounced the approval of the Investigational New Drug (IND) by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to conduct the clinical trial of a novel B7-H3 targeted ADC ICP-B794.

CanSinoBIO Launches Pneumococcal Vaccine: An Innovative Choice to Safeguard Children's Health

ACN NewswireJune 20, 2025

LTS and Nualtis Announce Strategic Cooperation to Expand Global Manufacturing Capabilities, Accelerate Market Expansion, and Ensure Customer Success

PR NewswireJune 25, 2025

M&As this week: Guanhao Biotech, Cancer Genetics, Alvogen | Pharmasources.com

Hua Medicine Announces at 2025 ADA Scientific Sessions that Dorzagliatin Combined With DPP-4 Inhibitor Shows Promise in Reducing Blood Lipids While Restoring Glucose Homeosta

ACN NewswireJune 23, 2025

Hua Medicine announced today that the Company presented the latest research results of dorzagliatin, its global first-in-class glucokinase activator (GKA), at the 85th Scientific Sessions of the American Diabetes Association (ADA).

亚洲欧美不卡高清在线观看,伊人久久大香线蕉午夜av,亚洲综合色区在线观看,中文在线中文a,真正免费的毛片

M&As this week: Guanhao Biotech, Cancer Genetics, Alvogen

Related News

InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China

CanSinoBIO Launches Pneumococcal Vaccine: An Innovative Choice to Safeguard Children's Health

LTS and Nualtis Announce Strategic Cooperation to Expand Global Manufacturing Capabilities, Accelerate Market Expansion, and Ensure Customer Success

Hua Medicine Announces at 2025 ADA Scientific Sessions that Dorzagliatin Combined With DPP-4 Inhibitor Shows Promise in Reducing Blood Lipids While Restoring Glucose Homeosta

You may like
More>>

亚洲欧美不卡高清在线观看,伊人久久大香线蕉午夜av,亚洲综合色区在线观看,中文在线中文a,真正免费的毛片

M&As this week: Guanhao Biotech, Cancer Genetics, Alvogen

Related News

InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China

CanSinoBIO Launches Pneumococcal Vaccine: An Innovative Choice to Safeguard Children's Health

LTS and Nualtis Announce Strategic Cooperation to Expand Global Manufacturing Capabilities, Accelerate Market Expansion, and Ensure Customer Success

Hua Medicine Announces at 2025 ADA Scientific Sessions that Dorzagliatin Combined With DPP-4 Inhibitor Shows Promise in Reducing Blood Lipids While Restoring Glucose Homeosta

You may likeMore>>

You may like
More>>